Vendor comparison · 2026
Abaloparatide vendors: 0 compared on COAs and price
OtherAlso known as BA058, Tymlos
Evidence tier
Substantial published literature
404 publications over 12 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 404
- researched since 2014
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Abaloparatide certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for Abaloparatide is on record. 0 vendors carrying Abaloparatide are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Abaloparatide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of Abaloparatide is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Abaloparatide names a laboratory this index could identify.
Every certificate record
No certificate record for Abaloparatide is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2014 — 12 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
404 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Abaloparatide?
A synthetic 34-amino-acid analogue of parathyroid-hormone-related protein (PTHrP). It is an approved prescription medicine for osteoporosis.
Studied in published research for osteoporosis and bone formation.
Regulatory status
Abaloparatide is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — JAMA (2016)
Peer-reviewed article indexed in PubMed, published in JAMA (2016).
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis — Journal of bone and mineral metabolism (2025)
Peer-reviewed article indexed in PubMed, published in Journal of bone and mineral metabolism (2025).
- Abaloparatide — Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases (2016)
Peer-reviewed article indexed in PubMed, published in Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases (2016).
- Abaloparatide: A new pharmacological option for osteoporosis — American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2019)
Peer-reviewed article indexed in PubMed, published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2019).
- Abaloparatide: A review of preclinical and clinical studies — European journal of pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in European journal of pharmacology (2021).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.